Overview

Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole

Status:
Recruiting

Trial end date:
2022-09-15

Target enrollment:

Participant gender:

Summary

SIR-POSA is a phase II trial of peripheral blood stem cell (PBSC) transplantation from a partially compatible family (Haplo) donor in patients with a blood tumor (myelodysplastic syndrome (MDS) and acute leukemia) treated for the prevention of primary fungal infections with posaconazole. The aim is evaluate the composite end-point graft-versus-host disease-free, relapse-free survival (GRFS) in these patients and evaluate the feasibility and efficacy of posaconazole oral tablets as primary antifungal prophylaxis.

Phase:

Phase 2

Details

Lead Sponsor:

Ciceri Fabio

Treatments:

Antifungal Agents
Busulfan
Clotrimazole
Fludarabine
Fludarabine phosphate
Miconazole
Posaconazole
Thiotepa
Treosulfan